Clinical trials: Unresectable Malignant Neoplasm
Metastatic or Unresectable Cutaneous Melanoma
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC)…
- Trial name
- NCT01763164
- Testing
- MEK162, Dacarbazine
- Where
- 229 sites in United States, Argentina and 25 more
- Volunteers
- 402 people
- Sponsor
- Pfizer
Cutaneous Squamous Cell Carcinoma
Treatment With Nab-paclitaxel in Cutaneous SCC
This is an investigator initiated phase II study to assess the efficacy of a chemotherapy called nab-paclitaxel as first line cytotoxic chemotherapy in subjects with unresectable locally advanced or metastatic cutaneous squamous…
- Trial name
- NCT02076243
- Testing
- nab-paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
Liposarcomas are soft tissue sarcomas most frequent. We distinguish three subtypes on the basis of their histological and cytogenetic characteristics: well-differentiated liposarcoma / dedifferentiated, myxoid liposarcoma and /…
- Trial name
- APLIPO (NCT01876043)
- Testing
- plitidepsin
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut Bergonié
Liver Cancer, Metastatic Cancer
Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
RATIONALE: Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells.
- Conditions
- Liver Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00019604
- Testing
- computed tomography, magnetic resonance imaging, positron emission tomography
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
The purpose of this study was to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.
- Trial name
- NCT02625610
- Testing
- Avelumab, Oxaliplatin, 5-Fluorouracil
- Where
- 200 sites in United States, Australia and 15 more
- Volunteers
- 499 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Melanoma
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab.
- Trial name
- SPOTLIGHT203 (NCT04570332)
- Testing
- BO-112 plus pembrolizumab, Tissue Biopsies
- Where
- 19 sites in France, Spain
- Volunteers
- 42 people
- Sponsor
- Highlight Therapeutics
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent)…
- Conditions
- Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02304458
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
HER2 Positive Breast Cancer
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma.
- Trial name
- HER2CLIMB (NCT02614794)
- Testing
- tucatinib, capecitabine, trastuzumab
- Where
- 176 sites in United States, Australia and 13 more
- Volunteers
- 612 people
- Sponsor
- Seagen Inc.
Sarcoma
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with unresectable or…
- Trial name
- NCT00068367
- Testing
- erlotinib hydrochloride
- Where
- 101 sites in United States
- Volunteers
- 24 people
- Sponsor
- SWOG Cancer Research Network